BMS' Purchase Of Amira: When An Acquisition Is Really An Asset Sale
This article was originally published in Start Up
Bristol-Myers Squibb Co.'s purchase of Amira Pharmaceuticals Inc. for $325 million upfront and another $150 million in downstream milestones shows that prior licensing deals and multiple programs in a pipeline don't necessarily curb a start-up's acquisition potential, provided investors are thinking smartly about deal structures that create separate value streams for the various products in the portfolio.
You may also be interested in...
Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.
Versant and Celgene have partnered again to launch a build-to-buy biotech, this time focusing on inflammatory bowel disease.
Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”